NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing